On Feb 14, Yizhao Biopharmaceutical pilot production and R&D base located in Beijing E-Town was put into operation. 

After reaching full capacity, the park is expected to have a production capacity of 100,000 liters of raw liquid, making it the largest biopharmaceutical CDMO (contract development and manufacturing organization) service base in Beijing.

"The first phase of the base has been completed and put into operation, with a construction area of 142,500 square meters, including 17 production and auxiliary facilities. The first batch of ten production lines of 2,000-liter raw liquid has been put into use," said Dong Yang, director of Strategic Development Department at JOINN Biologics.

Rendering of Yizhao Biopharmaceutical pilot production and R&D base [Photo/beijingetown.com.cn]

Walking into the park, several silver-gray and red "spacecraft-like" buildings exude a strong sense of technology. One three-story raw liquid production building is arranged with the base's first 2,000-liter scale disposable raw liquid production workshop. 

"The layout of the workshop is closely integrated with the production process. The third floor, the first step in raw liquid production, houses the cell fermentation workshop. The second floor is mainly the protein purification workshop, and the first floor is the formulation workshop for filling the produced raw liquid," said Su Jun, director of the Pilot Production Department of JOINN Biologics. 

The three 2,000-liter disposable raw liquid production lines are laid out from the third floor to the first floor. To strictly control the quality and reduce pollution risks, the workshop adopts a customized layout, fully equipped with internationally advanced production equipment, and uses wall-through pipelines to transport products. 

"For example, when the cell culture on the third floor reaches a certain point, it can be directly transported to the next step of production on the second floor along the pipeline," Su Jun explained. Currently, these three production lines have been highly automated, which can effectively improve efficiency.

The Yizhao Biopharmaceutical pilot production and R&D base project covers a total area of more than 120 mu (8 hectares), with a total expected investment of over 3 billion yuan ($437.41 million).

After reaching full capacity, it will become one of the largest biopharmaceutical CDMO service bases in the country, providing end-to-end services covering large molecule drug development to large-scale production for global partners.